Abstract |
The effectivity of Sabal serrulata extract in the treatment of symptomatic prostatic hyperplasia was scrutinized in 38 patients. In the course of the 12-month treatment followed up by examinations, the subjective complaints abated in almost 3/4 of the cases. Adverse effects were not encountered. According to uroflowmetry, the average peak flow rate increased from 10.36 ml/s to 14.44 ml/s (p < 0.0001), while the average middle stream increased from 6.02 ml/s to 7.45 ml/s (p < 0.001). Urinary retention decreased or disappeared in more than 9/10 of the cases. The average amount of the residue decreased by 47 ml (p < 0.001). The average volume of the prostate was reduced by 10.6% (p < 0.02). On the basis of the favourable results, Sabal serrulata extract is recommended in the treatment of prostatic hyperplasia producing symptoms of mild and moderate severity.
|
Authors | J Kondás, V Philipp, G Diószeghy |
Journal | International urology and nephrology
(Int Urol Nephrol)
Vol. 28
Issue 6
Pg. 767-72
( 1996)
ISSN: 0301-1623 [Print] Netherlands |
PMID | 9089044
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Enzyme Inhibitors
- Fatty Acids
- IDS 89 Sabal serrulata extract
- Phytosterols
- Plant Extracts
|
Topics |
- Aged
- Enzyme Inhibitors
(therapeutic use)
- Fatty Acids
(therapeutic use)
- Humans
- Male
- Middle Aged
- Organ Size
(drug effects)
- Phytosterols
(therapeutic use)
- Plant Extracts
(therapeutic use)
- Prostate
(pathology)
- Prostatic Hyperplasia
(diagnosis, drug therapy)
- Severity of Illness Index
- Urodynamics
(drug effects)
|